NCT06389942View on ClinicalTrials.gov

Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

March 10, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions

Healthy

Interventions

DRUG

9MW3011

Single dose intravenously on day 1

DRUG

9MW3011 placebo

Single dose intravenously on day 1

Trial Locations (1)

Unknown

PKUcare Luzhong Hospital, Zibo

All Listed Sponsors

lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY